The Patent Finder

Terms ending in 2033

Acceleron Pharma Inc.

Every in-force patent on Acceleron Pharma Inc.'s record whose computed term ends in 2033, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 9,809,636Methods for Increasing Red Blood Cell Levels Comprising Administering BMP9
In force
 · High confidence
Suragani, Rajasekhar Naga Venkata SaiIn forceHigh confidence
US 10,344,066Methods and Compositions for Increasing Red Blood Cells
In force
 · High confidence
Suragani, Rajasekhar Naga Venkata SaiIn forceHigh confidence
US 10,829,534Methods and Compositions for Increasing Red Blood Cells
In force
 · Medium confidence
Suragani, Rajasekhar Naga Venkata SaiIn forceMedium confidence
US 11,807,673Methods and Compositions for Increasing Red Blood Cells
In force
 · Medium confidence
Suragani, Rajasekhar Naga Venkata SaiIn forceMedium confidence
US 8,058,229A Method of Increasing Red Blood Cell Levels or Treating Anemia in a Patient
In force
 · High confidence
Acceleron Pharma Inc.In forceHigh confidence
5 of 5 patents shown. Soonest term end first, then patent number.
1 of these is in force and held by Acceleron Pharma Inc..
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited